Skip to main content
Cambodia Hep-C
War in Gaza:: find out how we're responding
Learn more
Worldwide, an estimated 58 million people are infected with the hepatitis C virus, with about 1.5 million new infections occurring per year.

While hepatitis C can be cured, few people have access to treatment.  

A blood-borne virus that attacks the liver, hepatitis C kills hundreds of thousands of people each year, mostly from resulting complications, usually cirrhosis or liver cancer.

While hepatitis C is found worldwide, the vast majority of people with the disease live in developing countries; China, India, Egypt, and Indonesia are particularly affected.

Hepatitis C is a curable disease, but millions don't have access to treatment due to high prices.


MSF Access Campaign

Quick facts about hepatitis C

When Big Pharma plays for keeps, who wins and who loses? (ENG)

When Big Pharma plays for keeps, who wins and who loses? (ENG)

When Big Pharma plays for keeps, who wins and who loses?

In this video, we follow the development of sofosbuvir, a true breakthrough drug for hepatitis C, a severe virus that attacks the liver and can be deadly.

The story of sofosbuvir illustrates how research and development for new prescription drugs really works.

After a scientist who got millions in tax-dollars started a small company that did the long work of discovering a new medicine, and showed that it was safe and effective, a giant corporation bought up the next big blockbuster drug and cashed in.

As the new owner of sofosbuvir, Gilead continued clinical trials to learn more about the drug’s effectiveness, safety, side-effects and dosage before seeking government approval to bring the new drug to market.

Gilead first set the price for sofosbuvir at $1000 per pill. That made its worth per gram 67 times greater than gold, but research shows that it only costs $42 to produce.

Libya: detention centres in Tripoli

Providing assistance to migrants and refugees

Voices from the Field 23 Jun 2017
MSF Clinic Hepatitis C Unit
Hepatitis C

MSF joins Europe-wide action challenging patent on key hepatitis C drug

Press Release 26 Mar 2017
Killer diseases

Seven killer diseases under the microscope

Documentary 27 Jan 2017
Seeking malaria treatment around Aweil, South Sudan
Access to medicines

MSF urges governments to set medical research policies that align with people’s health needs

Press Release 13 Sep 2016
MSF TB Treatment in Mumbai, India

At EU-India Summit, India must defend its pharmacy of the developing world

Press Release 29 Mar 2016
MSF Clinic Hepatitis C Unit - Noor Alam #3

Stories from patients cured of hepatitis C at MSF’s Machar Clinic in Karachi

Voices from the Field 9 Mar 2016
MSF Clinic Hepatitis C Unit

When they are diagnosed with hepatitis C, patients think they will die

Voices from the Field 9 Mar 2016
Hepatitis C in Mumbai

Patent challenge hearing on Gilead hepatitis C drug sofosbuvir starts in India

Project Update 26 Feb 2016

Indian generic companies should reject Gilead’s controversial hepatitis C ‘Anti-Diversion’ programme

Press Release 19 Mar 2015
Advanced HIV management in Homa Bay
Medical Resource

MSF Field Research

We produce important research based on our field experience. So far, we have published articles in over 100 peer-reviewed journals. These articles have often changed clinical practice and have been used for humanitarian advocacy. All of these articles can be found on our dedicated Field Research website.

Visit site